Frequently asked questions
FAQ
Frequently asked questions
China market entry questions are usually framed around structure, registration, or market size. The more important questions concern commercial viability: whether demand exists, whether the right partners can be identified, and whether the economics support sustained entry. This FAQ addresses the questions that typically determine outcome.
Theme
China is the right market if your product has a specific, testable commercial use case - identified buyers, a reachable channel, and a price point that holds against domestic competition. The question is not whether China is a large opportunity. It is whether your specific commercial thesis is viable in your specific target segment. We can answer this before any full commercial capital is committed.
China market validation tests whether the specific assumptions your entry depends on hold in practice. It tests demand - are the buyers you expect motivated to buy, at the price you need, through the channel you can access? It tests partners - are the distributors that we have identified actually aligned with what you need them to do? And it tests financial feasibility - do the numbers work at realistic timelines and cost levels? The output is a go / no-go recommendation on full commercial commitment.
China market potential is primarily a question of product-market fit under Chinese conditions. The first assessment is whether the product solves a meaningful problem for a clearly identifiable Chinese buyer - at a price point and through a channel structure that can realistically hold against domestic competition. That is the hardest part of the commercial model to change later.
Beyond product-market fit, the assessment also considers operational capacity, financial resilience, decision-making speed, regulatory exposure, and the company's ability to sustain a longer commercial ramp-up period than most Western markets require. Cultural adaptability matters, but commercial alignment matters more. A disciplined company with a viable thesis will usually outperform an enthusiastic company without one.
China is not a single market. It is a collection of regional economies with different buyer behaviour, industrial structures, regulatory priorities, and levels of market maturity. The right entry region depends on where your specific commercial thesis is most likely to hold - not on which cities are internationally best known.
For many SMEs, the strongest entry point is not Beijing or Shanghai, but a specialised industrial or sector cluster where buyers, infrastructure, policy incentives, and distribution networks are already aligned around a specific industry. These regions are often less visible internationally, but commercially more accessible for foreign SMEs with relevant technology, products, or expertise.
Regional selection has direct consequences for distributor quality, regulatory complexity, pricing expectations, talent access, and commercial timelines. Choosing the right starting point can materially reduce both entry cost and execution risk.
A: Localisation in China is usually a commercial requirement, not a branding preference. The level of localisation required depends on the product category, buyer segment, regulatory exposure, and regional market being targeted - but very few products enter China entirely unchanged.
Localisation may involve language adaptation, packaging, documentation, product specifications, pricing structure, digital presence, or channel strategy. In some sectors, regional differences also matter: buyer expectations, procurement behaviour, and implementation standards can vary significantly between provinces and cities.
The objective is not to make the company appear Chinese. It is to remove unnecessary friction from adoption, procurement, and trust-building. The strongest market entries preserve the company's core positioning while adapting the parts of the commercial model that local conditions genuinely require.
The process follows the staged entry model. The first step is a structured export readiness assessment - evaluating whether and how your company is prepared to enter China. If the diagnostic confirms readiness, the minimum viable presence is established: the minimum legal and operational presence required to test commercial assumptions in-market. This is not entry; it is enabling infrastructure. Commercial validation then begins: in-market testing of demand, channel viability, and partner behaviour. If validation confirms a viable path, full entry structure is decided and built out. Each stage is scoped separately. No stage is entered without evidence supporting it.
If validation confirms a viable commercial path, the next decision is full entry structure: selecting the legal and commercial model that matches what validation revealed about demand, channel, and timeline. If validation does not confirm viability, Shaeps provides a clear statement of why and what conditions would need to change.
In most cases, yes - if the intention is serious market entry rather than early-stage exploration.
Shaeps distinguishes between initial validation and real market participation. The latter almost always requires a local entity.
Why a local entity matters
- Credibility and seriousness: Without a registered presence in China, you are typically not treated as a committed commercial actor. Many potential partners - particularly larger corporates - will not prioritise engagement, and in practice you are often excluded from meaningful long-term discussions.
- Access to public and institutional opportunities: Government bodies and state-owned enterprises are generally not accessible without a local entity. These channels are structurally important in many industries and often represent the most significant commercial opportunities.
- Commercial operability: Core business functions such as contracting, RMB payments, hiring, banking, and compliance are significantly constrained without a local structure.
- Regulatory access: Many sector-specific approvals and licences require a locally registered entity, making full market participation impossible without one.
- Incentives and support: Tax incentives, subsidies, and free trade zone benefits are typically reserved for locally established companies.
In a small number of cases - typically premium or “imported” positioning strategies - companies may operate without a local entity. This is the exception rather than the rule and is usually not scalable.
Bottom line, without a local entity, you are effectively observing the market, not participating in it. For serious entry and access to meaningful counterparties, establishing a Chinese entity is usually a prerequisite, not a later optimisation.
Not in the early validation phase, but it is strongly recommended before any serious commercial commitment. Remote work can support initial screening and partner identification, but it is not sufficient for final decisions.
- A physical visit is important because: Trust is built in person - key partners expect face-to-face engagement before committing
- Commercial alignment is clarified faster: Terms and expectations are rarely finalised properly remotely.
- Partner quality is easier to assess on the ground: Signals and context matter.
- Institutional access improves with presence: Larger corporates and public organisations expect senior in-person meetings.
Remote is sufficient for early-stage exploration. But serious partnerships and investment decisions in China typically require senior in-person visit.
Timelines vary by sector and regulatory complexity, but a typical Shaeps-led structured entry follows a staged process:
- Screening: 1 week
- Qualification: 4 weeks
- Business planning: 7 weeks
- Company formation & onboarding: 6 + 26 weeks
Regulation is the key variable. Depending on industry, required approvals can extend timelines significantly - from a few months to years in more regulated sectors.
Commercial structuring can move relatively fast. Regulatory clearance is the main driver of uncertainty and delay.
The cost of China market entry depends on the entry model and the stage reached. A distributor-led approach may appear substantially less costly than establishing a Wholly Foreign-Owned Enterprise before demand is confirmed. The largest cost variable is often whether commercial assumptions are tested before full operational structure is committed.
At the same time, entry structure also affects broader operational factors such as taxation, payment flows, regulatory obligations, and the practical ability to operate locally. These considerations vary significantly depending on sector, business model, and long-term market objectives.
Shaeps works on a no-cure-no-pay basis. Advisory fees are contingent on commercial outcomes - not on time spent, reports delivered, or process completed. The specific fee structure depends on the scope and stage of the engagement. The first conversation is at no cost.
No cure, no pay means Shaeps' advisory fees are contingent on results. If the entry produces commercial outcomes, Shaeps earns. If it does not, Shaeps does not. The model aligns the advisor's incentives directly with the client's commercial objectives and removes the conflict of interest that exists when advisory revenue depends on process length rather than on results.
Partner quality in China varies significantly. The key is not assumption-based trust, but structured verification combined with staged commitment.
Shaeps approaches this in three layers:
Network-based screening
We prioritise partners that are sourced through verified local networks and prior commercial relationships. This reduces exposure to intermediaries with limited operational substance.
Structured due diligence
Before any commitment, we verify core signals of legitimacy and capability:
- Business licence and legal registration status
- Ownership structure and beneficial control where possible
- Track record, case evidence and relevant client references
- Sector-specific operational capability (not just trading or intermediary activity)
Controlled engagement design
Risk is further reduced through how the relationship is structured:
- Start small before scaling commitments
- Avoid large upfront payments without performance evidence
- Require local legal review of contracts before signing
- Progress relationships in defined commercial stages rather than one-off agreements
Trust in China is not absent, but it is constructed differently. While relationships matter, modern commercial practice allows trust to be built through professional verification and structured engagement - not informal assumptions.
Unreliable partners are avoided through "guanxi", verification, staged exposure, and disciplined contracting.
For most SMEs, the most immediate China entry risks are commercial rather than regulatory. Demand that appeared validated through introductory meetings fails to convert into orders. Partners selected on access and credibility rather than operational alignment underperform. Timelines based on home market analogies miss by twelve months or more. These risks are compressible through the staged entry approach: validating the commercial thesis before full capital is committed. Regulatory and IP risk are real and require management, but should be addressed as operational requirements - not as the primary frame for the entry decision.
IP protection in China requires proactive registration under Chinese law - home country protection does not apply in China. Trademarks, patents, and trade secrets must be registered in China before entry to be enforceable. Beyond registration, IP risk management involves structuring partner agreements to restrict technology transfer, maintaining control over trade secrets through operational discipline, and - for technology-intensive companies - a clear assessment of what can be shared, with whom, and under what conditions.
Partner identification starts with a clear specification of what the right partner needs to do commercially - not with a list of who is available. The most common source of partner failure in China is selecting on surface credibility (market position, sector relationships, apparent scale) rather than on operational alignment with the specific commercial model. Shaeps structures the partner search around alignment first.
Distributor assessment covers three dimensions: sector capability (do they genuinely cover the segment you need, not nominally?), operational capacity (can they manage the logistical, regulatory, and commercial requirements of your product category?), and incentive alignment (are their commercial incentives structured so that your product is a genuine priority among the other principals they represent?). Most partner selection processes focus heavily on the first dimension and insufficiently on the third - which is typically the one that determines performance.
Yes. Client-sourced partners are fully integrated into the Shaeps validation process. However, they are treated no differently from any other candidate. We apply the same structured assessment to ensure commercial and operational fit.
Full qualification applies equally, independent validation is required, tit is assessed objectively, and promising leads are incorporated into the broader partner mapping and shortlisting workflow.
Shaeps focuses on identifying partners who can genuinely execute in-market, not simply express interest. We assess candidates across dimensions like:
- Capability fit: proven ability to operate in your specific value chain and sector
- Market access: real distribution reach, customer access, or institutional connectivity
- Incentive alignment: clear commercial motivation to prioritise your offering
- Execution credibility: track record of delivery, not just introductions or trading activity.
Leads are typically sourced through a combination of local networks, investor relationships, and on-the-ground commercial channels. However, sourcing is only the first filter.
Equally important is how partners behave in practice - responsiveness, commitment level, and willingness to take action under defined terms.
